Ronald Witteles

4.9/5

Biography

Dr. Ronald Witteles is a Cardiologist who specializes in the treatment of patients with Heart Failure. He has particular expertise in the treatment of Amyloidosis, Sarcoidosis, and cardiac complications of cancer therapy (sometimes called "CardioOncology"). He serves as Co-Director of the Stanford Amyloid Center, one of the world's leading centers for the care of patients with amyloidosis, and serves as Co-Director of the Stanford Multidisciplinary Sarcoidosis Program. He is an Associate Editor for JACC: CardioOncology, the world's leading journal dedicated to the field of CardioOncology. Dr. Witteles has published extensively in his areas of expertise, and has won many awards for his excellence in both patient care and education.

Dr. Witteles serves as Program Director for the Stanford Internal Medicine residency program -- directly supervising the training of more than 140 physicians each year. He was recognized by Stanford in 2020 with the award for 'Program Director of the Year'. He holds board certification in Internal Medicine, Cardiovascular Disease, and Advanced Heart Failure/Transplant Cardiology.

View Full Biography

Professional Summary

Education & Certifications

Board Certification: American Board of Internal Medicine, Advanced Heart Failure and Transplant Cardiology (2012)
Fellowship: Stanford University School of Medicine (2007) CA
Residency: Stanford University School of Medicine (2004) CA
- Residency: Stanford University School of Medicine (2003) CA
- Board Certification: American Board of Internal Medicine, Cardiovascular Disease (2007)
- Board Certification: American Board of Internal Medicine, Internal Medicine (2003)
- Chief Resident, Stanford University, Internal Medicine (2004)
- Internship: Stanford University School of Medicine (2001) CA
- M.D. with Honors, University of Chicago, Medicine (2000)
- B.A., Northwestern University, Biology/Neuroscience (1996)
- F.A.C.P., American College of Physicians, Internal Medicine (2010)
- F.A.C.C., American College of Cardiology, Cardiology (2008)
- Chief Fellow, Stanford University, Cardiovascular Medicine (2007)
- Medical Education: University of Chicago Pritzker (2000) IL

View More Education & Certifications

Honors & Awards

Calvin Fentress Research Fellowship, University of Chicago Pritzker School of Medicine (1999)
Charles Dorsey Armstrong Clinical Excellence Award, Stanford University Dept. of Internal Medicine (2003)
Clinical Excellence Award, Stanford University Division of Cardiovascular Medicine (2006)
- Clinical Research Award, Stanford Univ. Division of Cardiovascular Medicine (2007)
- David W. Rytand Award for Excellence in Clinical Teaching by a Department of Medicine faculty member, Stanford University Department of Internal Medicine (2009, 2010)
- First Author - Selected as one of 10 most important heart failure articles in 2004, Journal of the American College of Cardiology (2005)
- First Author - Selected as one of 15 most important heart failure articles in 2007, Journal of the American College of Cardiology (2008)
- Francis G. Ebaugh, Jr. Research Award, Stanford University Dept. of Internal Medicine (2001, 2002, 2003)
- M.D. with Honors (highest distinction by U. of Chicago), University of Chicago Pritzker School of Medicine (2000)
- National Associates' Research Award, American College of Physicians/American Society of Internal Medicine (2004)
- National Research Fellowship Award, Heart Failure Society of America (2006)
- Outstanding Clinical Teaching Award, Stanford University Dept. of Internal Medicine (2002, 2003)
- Timothy F. Beckett, Jr. Award for Excellence in Teaching by a Medicine Fellow, Stanford Univ. Dept. of Internal Medicine (2006)

View More Honors & Awards

Administrative Appointments

Associate Director, Coronary Care Unit (CCU) (2008 - 2009)
Co-Director, Stanford Amyloid Center (2008 - Present)
Co-Director, Stanford Multidisciplinary Sarcoidosis Program (2019 - Present)
- Program Director, Internal Medicine Residency Training Program (2011 - Present)
- Sr. Associate Program Director, Internal Medicine Residency Training Program (2009 - 2011)

View More Administrative Appointments

Publications

Insulin resistance in idiopathic dilated cardiomyopathy - A possible etiologic link
Witteles, R. M., Tang, W. H. W., Jamali, A. H., Chu, J. W., Reaven, G. M., & Fowler, M. B. (2004). Insulin resistance in idiopathic dilated cardiomyopathy - A possible etiologic link. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 44(1), 78–81.
Premature ventricular contractions causing pacemaker-mediated tachycardia: A failure of postventricular atrial refractory period after premature ventricular contraction extension?
Witteles, R., Engel, G., Wang, P. J., & Al-Ahmad, A. (2005). Premature ventricular contractions causing pacemaker-mediated tachycardia: A failure of postventricular atrial refractory period after premature ventricular contraction extension? HEART RHYTHM, 2(12), 1389–90.
Cardiomyopathy of insulin resistance.
Witteles, R. M., & Fowler, M. B. (2006). Cardiomyopathy of insulin resistance. Heart Failure Clinics, 2(1), 13–23.
- Impact of nesiritide on renal function in patients with acute decompensated failure an pre-existing renal dysfunction - A randomized, double-blind, placebo-controlled clinical trial
  Witteles, R. M., Kao, D., Christopherson, D., Matsuda, K., Vagelos, R. H., Schreiber, D., & Fowler, M. B. (2007). Impact of nesiritide on renal function in patients with acute decompensated failure an pre-existing renal dysfunction - A randomized, double-blind, placebo-controlled clinical trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 50(19), 1835–40.
- Insulin-resistant cardiomyopathy
  Witteles, R. M., & Fowler, M. B. (2008). Insulin-resistant cardiomyopathy. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 51(2), 93–102.
- Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma
  Kohrt, H., Logan, A., Temmins, C., Witteles, R., Liedtke, M., & Medeiros, B. (2008). Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. LEUKEMIA & LYMPHOMA, 49(3), 581–85.
- Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate
  Telli, M. L., Witteles, R. M., Fisher, G. A., & Srinivas, S. (2008). Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. ANNALS OF ONCOLOGY, 19(9), 1613–1618.
- Clinical problem-solving. Fool's Gold.
  Leeper, N. J., Dhaliwal, G., Saint, S., & Witteles, R. M. (2008). Clinical problem-solving. Fool's Gold. New England Journal of Medicine, 359(19), 2035–41.
- Heart Failure in Hispanics
  Vivo, R. P., Krim, S. R., Cevik, C., & Witteles, R. M. (2009). Heart Failure in Hispanics. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 53(14), 1167–75.
- Nesiritide, Heart Failure, and Renal Dysfunction: Irrational Exuberance or Throwing the Baby out with the Bathwater Editorial to: "Impact of Nesiritide on Renal Function and Mortality in Patients Suffering from Heart Failure" by Dontas et al.
  Witteles, R. M. (2009). Nesiritide, Heart Failure, and Renal Dysfunction: Irrational Exuberance or Throwing the Baby out with the Bathwater Editorial to: "Impact of Nesiritide on Renal Function and Mortality in Patients Suffering from Heart Failure" by Dontas et al. CARDIOVASCULAR DRUGS AND THERAPY, 23(3), 183–86.
- Measurement Precision in the Optimization of Cardiac Resynchronization Therapy
  Turcott, R. G., Witteles, R. M., Wang, P. J., Vagelos, R. H., Fowler, M. B., & Ashley, E. A. (2010). Measurement Precision in the Optimization of Cardiac Resynchronization Therapy. CIRCULATION-HEART FAILURE, 3(3), 395–404.
- Rosiglitazone Increases Myocardial Glucose Metabolism in Insulin-Resistant Cardiomyopathy
  Kao, D. P., Witteles, R. M., Quon, A., Wu, J. C., Gambhir, S. S., & Fowler, M. B. (2010). Rosiglitazone Increases Myocardial Glucose Metabolism in Insulin-Resistant Cardiomyopathy. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 55(9), 926–27.
- Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians Responding Optimally?
  Yoon, G. J., Telli, M. L., Kao, D. P., Matsuda, K. Y., Carlson, R. W., & Witteles, R. M. (2010). Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians Responding Optimally? JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 56(20), 1644–50.
- Radiation Therapy for Breast Cancer Buyer Beware
  Witteles, R. M. (2011). Radiation Therapy for Breast Cancer Buyer Beware. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 57(4), 453–54.
- Trastuzumab-Related Cardiac Dysfunction
  Telli, M. L., & Witteles, R. M. (2011). Trastuzumab-Related Cardiac Dysfunction. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 9(2), 243–49.
- Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?
  Witteles, R. M., Fowler, M. B., & Telli, M. L. (2011). Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented? HEART FAILURE CLINICS, 7(3), 333-?
- Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies
  Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2012). Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 31(3), 325–31.
- Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned?
  Witteles, R. M., & Telli, M. (2012). Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned? JOURNAL OF CLINICAL ONCOLOGY, 30(16), 1916–18.
- Use and overuse of left ventriculography
  Witteles, R. M., Knowles, J. W., Perez, M., Morris, W. M., Spettell, C. M., Brennan, T. A., & Heidenreich, P. A. (2012). Use and overuse of left ventriculography. AMERICAN HEART JOURNAL, 163(4), 617-?
- More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis
  Stevenson, R., Witteles, R., Damrose, E., Arai, S., Lafayette, R. A., Schrier, S., … Liedtke, M. (2012). More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 138(5), 509–11.
- Broken Heart Syndrome (Takotsubo Cardiomyopathy) Triggered by Acute Mania: A Review and Case Report
  Maldonado, J. R., Pajouhi, P., & Witteles, R. (2013). Broken Heart Syndrome (Takotsubo Cardiomyopathy) Triggered by Acute Mania: A Review and Case Report. PSYCHOSOMATICS, 54(1), 74–79.
- Capecitabine-Induced Chest Pain Relieved by Diltiazem
  Ambrosy, A. P., Kunz, P. L., Fisher, G. A., & Witteles, R. M. (2012). Capecitabine-Induced Chest Pain Relieved by Diltiazem. AMERICAN JOURNAL OF CARDIOLOGY, 110(11), 1623–26.
- Dipeptidyl Peptidase 4 Inhibition Increases Myocardial Glucose Uptake in Nonischemic Cardiomyopathy
  Witteles, R. M., Keu, K. V., Quon, A., Tavana, H., & Fowler, M. B. (2012). Dipeptidyl Peptidase 4 Inhibition Increases Myocardial Glucose Uptake in Nonischemic Cardiomyopathy. JOURNAL OF CARDIAC FAILURE, 18(10), 804–9.
- The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis
  Dinner, S., Witteles, W., Witteles, R., Lam, A., Arai, S., Lafayette, R., … Liedtke, M. (2013). The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis. BRITISH JOURNAL OF HAEMATOLOGY, 161(3), 367–72.
- Cardiac Testing to Manage Cardiovascular Risk in Cancer Patients
  Davis, M., & Witteles, R. M. (2013). Cardiac Testing to Manage Cardiovascular Risk in Cancer Patients. SEMINARS IN ONCOLOGY, 40(2), 147–55.
- Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.
  Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., Lafayette, R., … Liedtke, M. (2013). Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement. Haematologica, 98(10), 1593–99.
- AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin
  Penchala, S. C., Connelly, S., Wang, Y., Park, M. S., Zhao, L., Baranczak, A., … Alhamadsheh, M. M. (2013). AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 110(24), 9992–97.
- B-type natriuretic peptide is effective therapy before cardiac transplantation
  B-type natriuretic peptide is effective therapy before cardiac transplantation. (2004). Annals of Internal Medicine, 141(11).
- A new provocative test for the diagnosis of pheochromocytoma?
  A new provocative test for the diagnosis of pheochromocytoma? (2001). American Journal of Anesthesiology, 28.
- Adult-onset nesidioblastosis causing hypoglycemia: An important clinical entity and continuing treatment dilemma
  Adult-onset nesidioblastosis causing hypoglycemia: An important clinical entity and continuing treatment dilemma. (2001). Archives of Surgery, 136(6).
- Episodic hypertension associated with sitting on hard surfaces
  Episodic hypertension associated with sitting on hard surfaces. (2001). Journal of General Internal Medicine, 16.
- Sensitivity of diagnostic and localization tests for pheochromocytoma in clinical practice
  Sensitivity of diagnostic and localization tests for pheochromocytoma in clinical practice. (2000). Archives of Internal Medicine, 160(16).
- Safe and cost-effective preoperative preparation of patients with pheochromocytoma
  Safe and cost-effective preoperative preparation of patients with pheochromocytoma. (2000). Anesthesia and Analgesia, 91(2).
- Neuroendocrine tumors of the pancreas
  Neuroendocrine tumors of the pancreas. (2002). The Practice of General Surgery.
- Parathyroid carcinoma
  Parathyroid carcinoma. (2002). Surgery of the Thyroid and Parathyroid Glands.
- Reversibility of trastuzumab cardiotoxicity: Is the concept alive and well?
  Reversibility of trastuzumab cardiotoxicity: Is the concept alive and well? (2007). Journal of Clinical Oncology, 25(34).
- Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma
  Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. (2008). Leukemia and Lymphoma, 49.
- Trastuzumab cardiotoxicity: Clinical management of asymptomatic declines in left ventricular function
  Trastuzumab cardiotoxicity: Clinical management of asymptomatic declines in left ventricular function. (2008). The American Journal of Hematology/Oncology, 7(1).
- High prevalence of impaired glucose metabolism in patients with idiopathic dilated cardiomyopathy
  Jamali, A. H., Witteles, R. M., Tang, W. H. W., Chu, J. W., Reaven, G. M., & Fowler, M. B. (2002). High prevalence of impaired glucose metabolism in patients with idiopathic dilated cardiomyopathy. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 39(5), 181A–181A.
- Reversibility of trastuzumab cardiotoxicity: Is the concept alive and well? Reply
  Telli, M. L., Carlson, R. W., Guardino, A. E., Hunt, S. A., & Witteles, R. M. (2007). Reversibility of trastuzumab cardiotoxicity: Is the concept alive and well? Reply. JOURNAL OF CLINICAL ONCOLOGY, 25(34), 5533–34.
- Insulin resistance in chronic heart failure - Reply
  Witteles, R. M., & Fowler, M. B. (2008). Insulin resistance in chronic heart failure - Reply. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 52(3), 239–40.
- Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies: Are Clinicians Responding Appropriately?
  Yoon, G., Telli, M., Kao, D., Matsuda, K., & Witteles, R. (2009). Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies: Are Clinicians Responding Appropriately? JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 53(10), A173–A173.
- Treating Asymptomatic Chemotherapy-Induced Cardiac Dysfunction A Chance That Cardiologists and Oncologists Should Not Miss Reply
  Witteles, R. M., Yoon, G., Telli, M., Kao, D. P., Matsuda, K. Y., & Carlson, R. W. (2011). Treating Asymptomatic Chemotherapy-Induced Cardiac Dysfunction A Chance That Cardiologists and Oncologists Should Not Miss Reply. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 57(17), 1790–91.
- Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies: Are clinicians responding appropriately?
  Telli, M. L., Yoon, G., Kao, D., Matsuda, K., & Witteles, R. M. (2009). Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies: Are clinicians responding appropriately? JOURNAL OF CLINICAL ONCOLOGY, 27(15).
- Overdiagnosis of Left Ventricular Noncompaction
  Singh, G. D., & Witteles, R. M. (2010). Overdiagnosis of Left Ventricular Noncompaction. JOURNAL OF CARDIAC FAILURE, 16(8), S107–S107.
- OVERUSE OF LEFT VENTRICULOGRAPHY
  Witteles, R., Knowles, J. W., Perez, M., Morris, W. H., Spettell, C. M., Brennan, T. A., & Heidenreich, P. A. (2011). OVERUSE OF LEFT VENTRICULOGRAPHY. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 57(14), E1289–E1289.
- Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy
  Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., & Witteles, R. M. (2011). Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy. JOURNAL OF CARDIAC FAILURE, 17(8), S45–S46.
- A Pilot Study of Melphalan, Lenalidomide and Dexamethasone In AL Amyloidosis: Interim Results
  Afghahi, A., Witteles, W., Witteles, R., Liedtke, M., Lafayette, R., Arai, S., & Schrier, S. L. (2010). A Pilot Study of Melphalan, Lenalidomide and Dexamethasone In AL Amyloidosis: Interim Results. BLOOD, 116(21), 810–11.
- Incidence and severity of cardiotoxicity in metastatic renal cell carcinoma (RCC) patients treated with targeted therapies.
  Hall, P. S., Witteles, R., Srinivas, S., & Harshman, L. C. (2012). Incidence and severity of cardiotoxicity in metastatic renal cell carcinoma (RCC) patients treated with targeted therapies. JOURNAL OF CLINICAL ONCOLOGY, 30(15).
- Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
  Esler, M. D., Krum, H., Sobotka, P. A., Schlaich, M. P., Schmieder, R. E., Boehm, M., … Massaro, J. M. (2010). Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. LANCET, 376(9756), 1903–9.
- Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis
  Varr, B. C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R. A., Arai, S., … Witteles, R. M. (2014). Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. HEART RHYTHM, 11(1), 158–62.
- Variation in Use of Left Ventriculography in the Veterans Affairs Health Care System
  Heidenreich, P. A., Lin, S., Knowles, J. W., Perez, M., Maddox, T. M., Ho, M. P., … Witteles, R. M. (2013). Variation in Use of Left Ventriculography in the Veterans Affairs Health Care System. CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 6(6), 687–93.
- The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients.
  Hall, P. S., Harshman, L. C., Srinivas, S., & Witteles, R. M. (2013). The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients. JACC. Heart Failure, 1(1), 72–78.
- Cancer therapy-induced left ventricular dysfunction: interventions and prognosis.
  Thakur, A., & Witteles, R. M. (2014). Cancer therapy-induced left ventricular dysfunction: interventions and prognosis. Journal of Cardiac Failure, 20(3), 155–58.
- Radiation-induced heart disease: an under-recognized entity?
  Davis, M., & Witteles, R. M. (2014). Radiation-induced heart disease: an under-recognized entity? Current Treatment Options in Cardiovascular Medicine, 16(6), 317-?
- Reply to "heart failure and breast cancer: emerging controversies regarding some cardioprotective strategies".
  Witteles, R. M., & Thakur, A. (2014). Reply to "heart failure and breast cancer: emerging controversies regarding some cardioprotective strategies". Journal of Cardiac Failure, 20(6), 457-?
- Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era.
  Davis, M. K., Kale, P., Liedtke, M., Schrier, S., Arai, S., Wheeler, M., … Witteles, R. M. (2015). Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era. American Journal of Transplantation , 15(3), 650–58.
- Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy
  Davis, M. K., Lee, P. H. U., & Witteles, R. M. (2015). Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 34(5), 658–66.
- The State of Medical Student Performance Evaluations: Improved Transparency or Continued Obfuscation?
  Hom, J., Richman, I., Hall, P., Ahuja, N., Harman, S., Harrington, R., & Witteles, R. (2016). The State of Medical Student Performance Evaluations: Improved Transparency or Continued Obfuscation? Academic Medicine , 91(11), 1534–39.
- Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity
  Burridge, P. W., Li, Y. F., Matsa, E., Wu, H., Ong, S.-G., Sharma, A., … Wu, J. C. (2016). Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. NATURE MEDICINE, 22(5), 547–56.
- Patient Outcomes when Housestaff Exceed 80 Hours per Week.
  Ouyang, D., Chen, J. H., Krishnan, G., Hom, J., Witteles, R., & Chi, J. (2016). Patient Outcomes when Housestaff Exceed 80 Hours per Week. American Journal of Medicine, 129(9), 993–99 e1.
- A resident-created hospitalist curriculum for internal medicine housestaff.
  Kumar, A., Smeraglio, A., Witteles, R., Harman, S., Nallamshetty, S., Rogers, A., … Ahuja, N. (2016). A resident-created hospitalist curriculum for internal medicine housestaff. Journal of Hospital Medicine, 11(9), 646–49.
- Genotype and Phenotype of Transthyretin Cardiac Amyloidosis THAOS (Transthyretin Amyloid Outcome Survey)
  Maurer, M. S., Hanna, M., Grogan, M., Dispenzieri, A., Witteles, R., Drachman, B., … Rapezzi, C. (2016). Genotype and Phenotype of Transthyretin Cardiac Amyloidosis THAOS (Transthyretin Amyloid Outcome Survey). JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 68(2), 161–72.
- Biomarkers as Predictors of Cardiac Toxicity From Targeted Cancer Therapies
  Witteles, R. M. (2016). Biomarkers as Predictors of Cardiac Toxicity From Targeted Cancer Therapies. JOURNAL OF CARDIAC FAILURE, 22(6), 459–64.
- Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).
  Maurer, M. S., Hanna, M., Grogan, M., Dispenzieri, A., Witteles, R., Drachman, B., … Rapezzi, C. (2016). Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). Journal of the American College of Cardiology, 68(2), 161–72.
- The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients
  Hall, P. S., Harshman, L. C., Srinivas, S., & Witteles, R. M. (2013). The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients. JACC-HEART FAILURE, 1(1), 72–78.
- Accreditation Council for Graduate Medical Education (ACGME) Milestones-Time for a Revolt?
  Witteles, R. M., & Verghese, A. (2016). Accreditation Council for Graduate Medical Education (ACGME) Milestones-Time for a Revolt? JAMA Internal Medicine, 176(11), 1599–1600.
- A high value care curriculum for interns: a description of curricular design, implementation and housestaff feedback.
  Hom, J., Kumar, A., Evans, K. H., Svec, D., Richman, I., Fang, D., … Shieh, L. (2017). A high value care curriculum for interns: a description of curricular design, implementation and housestaff feedback. Postgraduate Medical Journal.
- Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry).
  Tuzovic, M., Kobayashi, Y., Wheeler, M., Barrett, C., Liedtke, M., Lafayette, R., … Witteles, R. (2017). Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry). The American Journal of Cardiology, 120(8), 1381–86.
- A 15-year review of the Stanford Internal Medicine Residency Program: predictors of resident satisfaction and dissatisfaction
  Kahn, J. S., Witteles, R. M., Mahaffey, K. W., Desai, S. A., Ozdalga, E., & Heidenreich, P. A. (2017). A 15-year review of the Stanford Internal Medicine Residency Program: predictors of resident satisfaction and dissatisfaction. ADVANCES IN MEDICAL EDUCATION AND PRACTICE, 8, 559–66.
- Independent AV/VV pacing optimization requires operation along mechanical AV delay isochrones
  Turcott, R. G., Witteles, R., Wang, P. J., & Ashley, E. A. (2008). Independent AV/VV pacing optimization requires operation along mechanical AV delay isochrones. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 51(10), A21.
- Impedance cardiography is superior to echocardiographic methods for pacing interval optimization
  Turcott, R. G., Witteles, R. M., Wang, P. J., Vagelos, R. H., Fowler, M. B., & Ashley, E. A. (2008). Impedance cardiography is superior to echocardiographic methods for pacing interval optimization. JOURNAL OF CARDIAC FAILURE, 14(6), S65.
- AL Amyloidosis and Concomitant Myeloma: Time to Reconsider Assumptions.
  Witteles, W., Witteles, R., Liedtke, M., Arai, S., Lafayette, R., George, T. I., & Schrier, S. L. (2010). AL Amyloidosis and Concomitant Myeloma: Time to Reconsider Assumptions. BLOOD. AMER SOC HEMATOLOGY.
- Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis
  Kaufman, G. P., Schrier, S. L., Lafayette, R. A., Arai, S., Witteles, R. M., & Liedtke, M. (2017). Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. BLOOD, 130(7), 900–902.
- SERIAL CARDIAC FDG-PET IN THE DIAGNOSIS AND THERAPEUTIC GUIDANCE OF PATIENTS WITH CARDIAC SARCOIDOSIS: A STANFORD EXPERIENCE
  Ning, N., Guo, H. H., Jagaru, A., Mittra, E., Fowler, M., & Witteles, R. (2018). SERIAL CARDIAC FDG-PET IN THE DIAGNOSIS AND THERAPEUTIC GUIDANCE OF PATIENTS WITH CARDIAC SARCOIDOSIS: A STANFORD EXPERIENCE. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 71(11), 1690.
- Atrial Septal Defect as Unexpected Cause of Pulmonary Artery Hypertension
  Parikh, R., Boyd, J., Lee, D. P., & Witteles, R. (2018). Atrial Septal Defect as Unexpected Cause of Pulmonary Artery Hypertension. TEXAS HEART INSTITUTE JOURNAL, 45(1), 42–44.
- Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor A Case Report
  Gerson, J. N., Witteles, R. M., Chang, D. T., Beygui, R. E., Iagaru, A. H., & Kunz, P. L. (2017). Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor A Case Report. PANCREAS, 46(10), 1381–85.
- 18F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition.
  Baratto, L., Park, S. Y., Hatami, N., Gulaka, P., Vasanawala, S., Yohannan, T. K., … Iagaru, A. (2018). 18F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition. EJNMMI Research, 8(1), 66.
- Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis
  Yen, T., Chen, F., Witteles, R., Liedtke, M., & Nguyen, L. A. (2017). Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis. AMERICAN JOURNAL OF GASTROENTEROLOGY. NATURE PUBLISHING GROUP.
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
  Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., … Rapezzi, C. (2018). Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. The New England Journal of Medicine.
- WHOLE HEART OF THE MATTER
  Parikh, R., Boyd, J., Lee, D., & Witteles, R. (2017). WHOLE HEART OF THE MATTER. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC.
- Prevalence and Financial Impact of Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting: A Retrospective Analysis
  Mou, E., Kwang, H., Hom, J., Shieh, L., Ahuja, N., Harman, S., … Berube, C. (2016). Prevalence and Financial Impact of Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting: A Retrospective Analysis. BLOOD. AMER SOC HEMATOLOGY.
- The State of Medical Student Performance Evaluations: Improved Transparency or Continued Obfuscation?
  Hom, J., Richman, I., Hall, P., Ahuja, N., Harman, S., Harrington, R., & Witteles, R. (2016). The State of Medical Student Performance Evaluations: Improved Transparency or Continued Obfuscation? ACADEMIC MEDICINE, 91(11), 1534–39.
- Hematologic Responses and Cardiac Organ Improvement in Patients with Heavily Pretreated Cardiac Immunoglobulin Light Chain (AL) Amyloidosis Receiving Daratumumab
  Kaufman, G., Witteles, R., Wheeler, M., Ulloa, P., Lugtu, M., Arai, S., … Liedtke, M. (2016). Hematologic Responses and Cardiac Organ Improvement in Patients with Heavily Pretreated Cardiac Immunoglobulin Light Chain (AL) Amyloidosis Receiving Daratumumab. BLOOD. AMER SOC HEMATOLOGY.
- Grading cardiac response in AL amyloidosis: implications for relapse and survival.
  Eckhert, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., … Liedtke, M. (2018). Grading cardiac response in AL amyloidosis: implications for relapse and survival. British Journal of Haematology.
- Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial: Sensitivity Analyses Further Support the Primary Results
  Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P., Merlini, G., Cruz, M. W., … Rapezzi, C. (2018). Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial: Sensitivity Analyses Further Support the Primary Results. JOURNAL OF CARDIAC FAILURE, 24(11), 813.
- Safety, Tolerability and Transthyretin Stabilization by AG10: A Phase 2, Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients with Transthyretin Amyloid Cardiomyopathy and NYHA Class II/III Heart Failure
  Judge, D. P., Falk, R., Grogan, M., Heitner, S. B., Jacoby, D., Maurer, M., … Fox, J. C. (2018). Safety, Tolerability and Transthyretin Stabilization by AG10: A Phase 2, Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients with Transthyretin Amyloid Cardiomyopathy and NYHA Class II/III Heart Failure. CIRCULATION, 138(25), E770.
- Doxycycline and Ursodiol for ATTR Amyloidosis: Not Ready for Prime Time.
  Witteles, R. (2019). Doxycycline and Ursodiol for ATTR Amyloidosis: Not Ready for Prime Time. Journal of Cardiac Failure.
- Graded Cardiac Response Correlates with Relapse and Survival in AL Amyloidosis
  Eckhert, E. K., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., … Liedtke, M. (2018). Graded Cardiac Response Correlates with Relapse and Survival in AL Amyloidosis. BLOOD, 132.
- Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients with Cardiac Sarcoidosis.
  Ning, N., Guo, H. H., Iagaru, A., Mittra, E., Fowler, M., & Witteles, R. (2019). Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients with Cardiac Sarcoidosis. Journal of Cardiac Failure.
- Human Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Breast Cancer Patients.
  Kitani, T., Ong, S.-G. G., Lam, C. K., Rhee, J.-W. W., Zhang, J. Z., Oikonomopoulos, A., … Wu, J. C. (2019). Human Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Breast Cancer Patients. Circulation.
- REPLY: Increasingly Recognized Role of Right Ventricle Assessment in Cardiac Amyloidosis
  Amsallem, M., Witteles, R., & Haddad, F. (2019). REPLY: Increasingly Recognized Role of Right Ventricle Assessment in Cardiac Amyloidosis. JACC-HEART FAILURE, 7(3), 279–80.
- Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.
  Judge, D. P., Falk, R. H., Maurer, M. S., Shah, S. J., Witteles, R. M., Grogan, M., … Heitner, S. B. (2019). Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. Journal of the American College of Cardiology.
- Nesiritide does not cause renal dysfunction in acute decompensated heart failure: A randomized, double-blind, placebo-controlled clinical trial
  Witteles, R. M., Kao, D., Vagelos, R., Christopherson, D., Matsuda, K., Schreiber, D., & Fowler, M. B. (2007). Nesiritide does not cause renal dysfunction in acute decompensated heart failure: A randomized, double-blind, placebo-controlled clinical trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 49(9), 63A.
- B-type natriuretic peptide is effective therapy before care
  Witteles, R., Matsuda, K., & Fowler, M. B. (2004). B-type natriuretic peptide is effective therapy before care. ANNALS OF INTERNAL MEDICINE, 141(11), 895.
- FROM PALPITATIONS TO CARDIOVASCULAR COLLAPSE: THE STORY OF A PHEOCHROMOCYTOMA
  Flint, K. M., & Witteles, R. (2015). FROM PALPITATIONS TO CARDIOVASCULAR COLLAPSE: THE STORY OF A PHEOCHROMOCYTOMA. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 65(10), A618.
- Response to Letter Regarding Article, "Myocardial Protection During Cardiotoxic Chemotherapy"
  Witteles, R. M., & Bosch, X. (2016). Response to Letter Regarding Article, "Myocardial Protection During Cardiotoxic Chemotherapy". CIRCULATION, 133(15), E598.
- Myocardial Protection During Cardiotoxic Chemotherapy
  Witteles, R. M., & Bosch, X. (2015). Myocardial Protection During Cardiotoxic Chemotherapy. CIRCULATION, 132(19), 1835–45.
- Development of a reproducible FDG PET/CT cardiac imaging protocol for the evaluation of cardiac sarcoidosis
  Kulm, J., Mittra, E., Guo, H. H., Witteles, R., & Quon, A. (2013). Development of a reproducible FDG PET/CT cardiac imaging protocol for the evaluation of cardiac sarcoidosis. JOURNAL OF NUCLEAR MEDICINE, 54.
- Chemotherapy-Induced Left Ventricular Dysfunction: Interventions and Prognosis
  Thakur, A., & Witteles, R. M. (2013). Chemotherapy-Induced Left Ventricular Dysfunction: Interventions and Prognosis. JOURNAL OF CARDIAC FAILURE, 19(8), S86–S87.
- Therapy With a DPP-4 Inhibitor Increases Myocardial Glucose Uptake in Nonischemic Cardiomyopathy
  Witteles, R. M., Keu, K. V., Quon, A., Tavana, H., & Fowler, M. B. (2012). Therapy With a DPP-4 Inhibitor Increases Myocardial Glucose Uptake in Nonischemic Cardiomyopathy. JOURNAL OF CARDIAC FAILURE, 18(8), S10.
- Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
  Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., … Rapezzi, C. (2018). Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. NEW ENGLAND JOURNAL OF MEDICINE, 379(11), 1007–16.
- Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients With Cardiac Sarcoidosis
  Ning, N., Guo, H. H., Iagaru, A., Mittra, E., Fowler, M., & Witteles, R. (2019). Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients With Cardiac Sarcoidosis. JOURNAL OF CARDIAC FAILURE, 25(4), 307–11.
- Doxycycline and Ursodiol for ATTR Amyloidosis: Not Ready for Prime Time
  Witteles, R. M. (2019). Doxycycline and Ursodiol for ATTR Amyloidosis: Not Ready for Prime Time. JOURNAL OF CARDIAC FAILURE, 25(3), 154–55.
- F-18-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition
  Baratto, L., Park, S. Y., Hatami, N., Gulaka, P., Vasanawala, S., Yohannan, T. K., … Iagaru, A. (2018). F-18-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition. EJNMMI RESEARCH, 8.
- A high value care curriculum for interns: a description of curricular design, implementation and housestaff feedback
  Hom, J., Kumar, A., Evans, K. H., Svec, D., Richman, I., Fang, D., … Shieh, L. (2017). A high value care curriculum for interns: a description of curricular design, implementation and housestaff feedback. POSTGRADUATE MEDICAL JOURNAL, 93(1106), 725–29.
- Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer
  Kitani, T., Ong, S.-G., Lam, C. K., Rhee, J.-W., Zhang, J. Z., Oikonomopoulos, A., … Wu, J. C. (2019). Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer. CIRCULATION, 139(21), 2451–65.
- Grading cardiac response in AL amyloidosis: implications for relapse and survival
  Eckhert, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., … Liedtke, M. (2019). Grading cardiac response in AL amyloidosis: implications for relapse and survival. BRITISH JOURNAL OF HAEMATOLOGY, 186(1), 144–46.
- Emerging Therapies for Transthyretin Cardiac Amyloidosis.
  Alexander, K. M., Evangelisti, A., & Witteles, R. M. (2019). Emerging Therapies for Transthyretin Cardiac Amyloidosis. Current Treatment Options in Cardiovascular Medicine, 21(8), 40.
- Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.
  Witteles, R. M., Bokhari, S., Damy, T., Elliott, P. M., Falk, R. H., Fine, N. M., … Garcia-Pavia, P. (2019). Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. JACC. Heart Failure.
- Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy
  Judge, D. P., Heitner, S. B., Falk, R. H., Maurer, M. S., Shah, S. J., Witteles, R. M., … Fox, J. C. (2019). Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 74(3), 285–95.
- Thrombophilia testing in the inpatient setting: impact of an educational intervention.
  Kwang, H., Mou, E., Richman, I., Kumar, A., Berube, C., Kaimal, R., … Hom, J. (2019). Thrombophilia testing in the inpatient setting: impact of an educational intervention. BMC Medical Informatics and Decision Making, 19(1), 167.
- Genomics in medicine: a novel elective rotation for internal medicine residents.
  Geng, L. N., Kohler, J. N., Levonian, P., Bernstein, J. A., Ford, J. M., Ahuja, N., … Wheeler, M. (2019). Genomics in medicine: a novel elective rotation for internal medicine residents. Postgraduate Medical Journal.
- Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.
  Maurer, M. S., Bokhari, S., Damy, T., Dorbala, S., Drachman, B. M., Fontana, M., … Merlini, G. (2019). Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis. Circulation. Heart Failure, 12(9), e006075.
- Efficacy and Safety of Tafamidis Doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT)
  Hanna, M., Damy, T., Garcia-Pavia, P., Judge, D. P., Merlini, G., Maurer, M. S., … Witteles, R. (2019). Efficacy and Safety of Tafamidis Doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). JOURNAL OF CARDIAC FAILURE, 25(8), S77–S78.
- Diagnosis and Treatment of Cardiac Amyloidosis Related to Plasma Cell Dyscrasias.
  Alexander, K. M., Evangelisti, A., & Witteles, R. M. (2019). Diagnosis and Treatment of Cardiac Amyloidosis Related to Plasma Cell Dyscrasias. Cardiology Clinics, 37(4), 487–95.
- A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.
  Barrett, C. D., Dobos, K., Liedtke, M., Tuzovic, M., Haddad, F., Kobayashi, Y., … Witteles, R. M. (2019). A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis. JACC. Heart Failure.
- TNF-alpha inhibition for the treatment of cardiac sarcoidosis.
  Baker, M. C., Sheth, K., Witteles, R., Genovese, M. C., Shoor, S., & Simard, J. F. (2019). TNF-alpha inhibition for the treatment of cardiac sarcoidosis. Seminars in Arthritis and Rheumatism.
- Bone Scintigraphy Imaging for Transthyretin Cardiac Amyloidosis: Still Much to Learn.
  Alexander, K. M., & Witteles, R. M. (2020). Bone Scintigraphy Imaging for Transthyretin Cardiac Amyloidosis: Still Much to Learn. JACC. Cardiovascular Imaging.
- Long-Term Safety and Efficacy of AG10 in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study
  Judge, D., Heitner, S. B., Falk, R. H., Grogan, M., Jacoby, D. L., Maurer, M. S., … Fox, J. (2019). Long-Term Safety and Efficacy of AG10 in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study. CIRCULATION, 140(25), E966–E967.
- Organ responses with daratumumab therapy in previously treated AL amyloidosis.
  Chung, A., Kaufman, G. P., Sidana, S., Eckhert, E., Schrier, S. L., Lafayette, R. A., … Liedtke, M. (2020). Organ responses with daratumumab therapy in previously treated AL amyloidosis. Blood Advances, 4(3), 458–66.
- Management of Cardiac Amyloidosis: Do's and Don'ts.
  Alexander, K. M., & Witteles, R. M. (2019). Management of Cardiac Amyloidosis: Do's and Don'ts. The Canadian Journal of Cardiology.
- Human-induced Pluripotent Stem Cell-derived Cardiomyocytes as a Model for Trastuzumab-Induced Cardiac Dysfunction
  Kitani, T., Ong, S.-G., Lam, C. K., Rhee, J.-W., Zhang, J. Z., Oikonomopoulos, A., … Wu, J. C. (2019). Human-induced Pluripotent Stem Cell-derived Cardiomyocytes as a Model for Trastuzumab-Induced Cardiac Dysfunction. CIRCULATION RESEARCH. LIPPINCOTT WILLIAMS & WILKINS.
- Portable Ultrasound Device Usage and Learning Outcomes Among Internal Medicine Trainees: A Parallel-Group Randomized Trial.
  Kumar, A., Weng, Y., Wang, L., Bentley, J., Almli, M., Hom, J., … Kugler, J. (2020). Portable Ultrasound Device Usage and Learning Outcomes Among Internal Medicine Trainees: A Parallel-Group Randomized Trial. Journal of Hospital Medicine, 15(2), e1–e6.
- Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response
  Zhu, H., Rhee, J.-W., Cheng, P., Waliany, S., Chang, A., Witteles, R. M., … Wu, S. M. (2020). Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response. Curr Cardiol Rep, 22(5).
- Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty.
  Cheng, P., Zhu, H., Witteles, R. M., Wu, J. C., Quertermous, T., Wu, S. M., & Rhee, J.-W. W. (2020). Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty. Current Cardiology Reports, 22(5), 34.
- Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation.
  Barrett, C. D., Alexander, K. M., Zhao, H., Haddad, F., Cheng, P., Liao, R., … Witteles, R. M. (2020). Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation. JACC. Heart Failure.
- Correction to: Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response.
  Zhu, H., Rhee, J.-W., Cheng, P., Waliany, S., Chang, A., Witteles, R. M., … Wu, S. M. (2020). Correction to: Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response. Current Cardiology Reports, 22(5), 36.
- Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a Position Statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
  Lyon, A. R., Dent, S., Stanway, S., Earl, H., Brezden-Masley, C., Cohen-Solal, A., … Lenihan, D. (2020). Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a Position Statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. European Journal of Heart Failure.
- Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week.
  Hanna, M., Ruberg, F. L., Maurer, M. S., Dispenzieri, A., Dorbala, S., Falk, R. H., … Grogan, M. (2020). Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week. Journal of the American College of Cardiology, 75(22), 2851–62.
- Cardiac Scintigraphy With Technetium-99m-Labeled Bone -Seeking Tracers for Suspected Amyloidosis JACC Review Topic of the Week
  Hanna, M., Ruberg, F. L., Maurer, M. S., Dispenzieri, A., Dorbala, S., Falk, R. H., … Grogan, M. (2020). Cardiac Scintigraphy With Technetium-99m-Labeled Bone -Seeking Tracers for Suspected Amyloidosis JACC Review Topic of the Week. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 75(22), 2851–62.
- Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.
  Waliany, S., Lee, D., Witteles, R. M., Neal, J. W., Nguyen, P., Davis, M. M., … Zhu, H. (2020). Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. Annual Review of Pharmacology and Toxicology.
- REPLY: Should We Be for ASCT? If Yes, Then When?
  Witteles, R. M., & Barrett, C. D. (2020). REPLY: Should We Be for ASCT? If Yes, Then When? JACC-HEART FAILURE, 8(8), 696–97.
- Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner.
  Gertz, M., Adams, D., Ando, Y., Beirão, J. M., Bokhari, S., Coelho, T., … Merlini, G. (2020). Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Family Practice, 21(1), 198.
- A pilot study of F-18-FSPG SiPM-based PET/CT in patients referred for exclusion of active cardiac sarcoidosis and negative or non-diagnostic F-18-FDG PET/CT
  Duan, H., Hatami, N., Baratto, L., Davidzon, G., Aparici, C. M., Gambhir, S., … Iagaru, A. (2020). A pilot study of F-18-FSPG SiPM-based PET/CT in patients referred for exclusion of active cardiac sarcoidosis and negative or non-diagnostic F-18-FDG PET/CT. JOURNAL OF NUCLEAR MEDICINE, 61.
- Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
  Damy, T., Garcia-Pavia, P., Hanna, M., Judge, D. P., Merlini, G., Gundapaneni, B., … Witteles, R. (2020). Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study. European Journal of Heart Failure.
- Functional Capacity, Health-related Quality-of-life and Cardiac Biomarker Improvement with Tafamidis in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT)
  Hanna, M., Fine, N., Stewart, M., Gundapaneni, B., Sultan, M. B., & Witteles, R. (2020). Functional Capacity, Health-related Quality-of-life and Cardiac Biomarker Improvement with Tafamidis in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT). JOURNAL OF CARDIAC FAILURE, 26(10), S65.
- Temporal Trends of Wild-type Attr Amyloidosis in the Transthyretin Amyloidosis Outcomes Survey
  Nativi-Nicolau, J., Siu, A., Dispenzieri, A., Maurer, M. S., Rapezzi, C., Kristen, A., … Grogan, M. (2020). Temporal Trends of Wild-type Attr Amyloidosis in the Transthyretin Amyloidosis Outcomes Survey. JOURNAL OF CARDIAC FAILURE, 26(10), S82.
- Letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.
  Damy, T., Sultan, M. B., & Witteles, R. (2020). Letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'. European Journal of Heart Failure.
- Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis
  Chung, A., Kaufman, G. P., Sidana, S., Eckhert, E., Schrier, S., Arai, S., … Liedtke, M. (2019). Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis. BLOOD. AMER SOC HEMATOLOGY.
- Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses
  Chung, A., Kaufman, G. P., Sidana, S., Iberri, D., Eckhert, E., Schrier, S., … Liedtke, M. (2019). Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses. BLOOD. AMER SOC HEMATOLOGY.
- Global Longitudinal Strain in Cardio-Oncology.
  Moslehi, J. J., & Witteles, R. M. (2021). Global Longitudinal Strain in Cardio-Oncology. Journal of the American College of Cardiology, 77(4), 402–4.
- Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis
  Zhu, H., Lee, D., Sarah, W., Galdos, F. X., D'Addabbo, J., Fowler, M. B., … Wu, S. M. (2020). Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis. CIRCULATION RESEARCH. LIPPINCOTT WILLIAMS & WILKINS.
- AL Amyloidosis for the Cardiologist and Oncologist Epidemiology, Diagnosis, and Management
  Witteles, R. M., & Liedtke, M. (2019). AL Amyloidosis for the Cardiologist and Oncologist Epidemiology, Diagnosis, and Management. JACC: CARDIOONCOLOGY, 1(1), 117–30.
- Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor
  Waliany, S., Sainani, K. L., Park, L. S., Zhang, C. A., Srinivas, S., & Witteles, R. M. (2019). Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor. JACC: CARDIOONCOLOGY, 1(1), 24–36.
- Avoiding Catastrophe: Understanding Free Light Chain Testing in the Evaluation of ATTR Amyloidosis.
  Witteles, R. M., & Liedtke, M. (2021). Avoiding Catastrophe: Understanding Free Light Chain Testing in the Evaluation of ATTR Amyloidosis. Circulation. Heart Failure, CIRCHEARTFAILURE120008225.
- Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis
  Spencer-Bonilla, G., Njoroge, J. N., Pearson, K., Witteles, R. M., Aras, M. A., & Alexander, K. M. (2021). Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis. Curr Cardiovasc Risk Rep.
- Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.
  Waliany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., … Zhu, H. (2021). Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors. JACC. CardioOncology, 3(1), 137–39.
- Corrigendum to 'TNF-alpha Inhibition for the Treatment of Cardiac Sarcoidosis' Seminars in Arthritis and Rheumatism. 2020 Jun;50(3):546-552.
  Baker, M. C., Sheth, K., Witteles, R., Genovese, M. C., Shoor, S., & Simard, J. F. (2021). Corrigendum to 'TNF-alpha Inhibition for the Treatment of Cardiac Sarcoidosis' Seminars in Arthritis and Rheumatism. 2020 Jun;50(3):546-552. Seminars in Arthritis and Rheumatism.
- Racial and Ethnic Disparities in Cardio-Oncology A Call to Action
  Fazal, M., Malisa, J., Rhee, J.-W., Witteles, R. M., & Rodriguez, F. (2021). Racial and Ethnic Disparities in Cardio-Oncology A Call to Action. JACC: CARDIOONCOLOGY, 3(2), 201–204.
- Racial and Ethnic Disparities in Cardio-Oncology: A Call to Action.
  Fazal, M., Malisa, J., Rhee, J.-W. W., Witteles, R. M., & Rodriguez, F. (2021). Racial and Ethnic Disparities in Cardio-Oncology: A Call to Action. JACC. CardioOncology, 3(2), 201–204.
- Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor.
  Waliany, S., Sainani, K. L., Park, L. S., Zhang, C. A., Srinivas, S., & Witteles, R. M. (2019). Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor. JACC. CardioOncology, 1(1), 24–36.
- AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management.
  Witteles, R. M., & Liedtke, M. (2019). AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management. JACC. CardioOncology, 1(1), 117–130.
- Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.
  Waliany, S., Zhu, H., Wakelee, H., Padda, S. K., Das, M., Ramchandran, K., … Neal, J. W. (2021). Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma. Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer.
- Mitochondria-Rich Extracellular Vesicles Rescue Patient-Specific Cardiomyocytes From Doxorubicin Injury: Insights Into the SENECA Trial.
  O'Brien, C. G., Ozen, M. O., Ikeda, G., Vaskova, E., Jung, J. H., Bayardo, N., … Yang, P. C. (2021). Mitochondria-Rich Extracellular Vesicles Rescue Patient-Specific Cardiomyocytes From Doxorubicin Injury: Insights Into the SENECA Trial. JACC. CardioOncology, 3(3), 428–440.
- Misconceptions and Facts About Cardiac Amyloidosis.
  Nguyen, F. D., Rodriguez Rivera, M., Krittanawong, C., Witteles, R., & Lenihan, D. J. (2021). Misconceptions and Facts About Cardiac Amyloidosis. The American Journal of Cardiology.
- Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey.
  Nativi-Nicolau, J., Siu, A., Dispenzieri, A., Maurer, M. S., Rapezzi, C., Kristen, A. V., … Grogan, M. (2021). Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey. JACC. CardioOncology, 3(4), 537–546.
- Cardiac Transplantation and Mechanical Circulatory Support in Amyloidosis.
  Witteles, R. M. (2021). Cardiac Transplantation and Mechanical Circulatory Support in Amyloidosis. JACC. CardioOncology, 3(4), 516–521.
- Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis
  Muchtar, E., Wisniowski, B., Palladini, G., Milani, P., Merlini, G., Schonland, S., … Gertz, M. (2021). Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
- Ibrutinib-associated atrial fibrillation treatment with catheter ablation.
  Kapoor, R., Fazal, M., Cheng, P., Witteles, R., Rhee, J.-W., & Baykaner, T. (2021). Ibrutinib-associated atrial fibrillation treatment with catheter ablation. HeartRhythm Case Reports, 7(11), 713–716.
- Graded cardiac response criteria for AL amyloidosis: the impact of depth of cardiac response on survival
  Muchtar, E. Y., Dispenzieri, A., Wisniowski, B., Palladini, G., Milani, P., Merlini, G., … Gertz, M. (2021). Graded cardiac response criteria for AL amyloidosis: the impact of depth of cardiac response on survival. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG MEDIA GROUP, LP.
- Arrhythmia Patterns in Patients on Ibrutinib.
  Fazal, M., Kapoor, R., Cheng, P., Rogers, A. J., Narayan, S. M., Wang, P., … Rhee, J.-W. (1800). Arrhythmia Patterns in Patients on Ibrutinib. Frontiers in Cardiovascular Medicine, 8, 792310.
- Developing Therapy for Transthyretin Amyloidosis.
  Campbell, C. M., Zhang, K., Lenihan, D. J., & Witteles, R. (1800). Developing Therapy for Transthyretin Amyloidosis. The American Journal of Medicine.
- High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning.
  Duffy, G., Cheng, P. P., Yuan, N., He, B., Kwan, A. C., Shun-Shin, M. J., … Ouyang, D. (2022). High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning. JAMA Cardiology.
- Constrictive Pericarditis Revealing Rare Case of ALH Amyloidosis With Underlying Lymphoplasmacytic Lymphoma (Waldenstrom Macroglobulinemia).
  Ho, V. V., O'Sullivan, J. W., Collins, W. J., Ozdalga, E., Bell, C. F., Shah, N. D., … Witteles, R. M. (2022). Constrictive Pericarditis Revealing Rare Case of ALH Amyloidosis With Underlying Lymphoplasmacytic Lymphoma (Waldenstrom Macroglobulinemia). JACC. Case Reports, 4(5), 271–275.
- Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis.
  Spencer-Bonilla, G., Njoroge, J. N., Pearson, K., Witteles, R. M., Aras, M. A., & Alexander, K. M. (2021). Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis. Current Cardiovascular Risk Reports, 15(6).
- The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity
  Huang, Y. V., Waliany, S., Lee, D., Galdos, F. X., Witteles, R. M., Neal, J. W., … Zhu, H. (2022). The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity. JACC: CardioOncology, 4(5).
- Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series
  Franquiz, M., Waliany, S., Xu, A., Hnatiuk, A., Wu, S., Cheng, P., … Zhu, H. (2023). Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series. JACC: CardioOncology, 839–841.
- Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research
  Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliany, S., Neal, J., … Zhu, H. (2023). Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research. Current Treatment Options in Cardiovascular Medicine.

View More Publications

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Closed Trials

Specializing In

Heart Failure

Practice Locations

Amyloid Center Stanford, CA

Stanford, CA

Amyloid Center

300 Pasteur Dr, 2nd Fl Rm A260

Stanford , CA 94305

(650) 725-6186

More Clinic Information

Heart Transplant Program Stanford, CA

Stanford, CA

Heart Transplant Program

300 Pasteur Dr, 2nd Fl Rm A21

Stanford , CA 94305

(650) 723-5468

More Clinic Information

Heart Failure Clinic at Stanford Stanford, CA

Stanford, CA

Heart Failure Clinic at Stanford

300 Pasteur Dr, 2nd Fl Rm A260

Stanford , CA 94305

(650) 724-4942

More Clinic Information

Important Information about Our Organizations and Physician Affiliation

Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.

Patient Ratings

(84 Ratings)

Overall Rating

4.9/5

View Ratings by Category

5.0/5

Friendliness

4.9/5

Explanations

5.0/5

Listens

4.9/5

Care provider's efforts to include you in decisions about your care

4.9/5

Recommended to others

0.0/5

Wait times

How Our Ratings Work

The Patients Ratings and comments are gathered from our Patient Satisfaction Survey and displayed in their entirety.

Patient Satisfaction Survey Disclaimer

Patient Reviews

(175 reviews)

Outstanding physician!

Oct 2024

•

Verified SHC Patient

Very clear, attentive, detailed, responsive, professional.

Aug 2024

•

Verified SHC Patient

Exceptional, very thorough in explaining the cause and treatment.

Aug 2024

•

Verified SHC Patient

I appreciate that the doctor knows my history and applies that information to the discussion and his decisions.

Aug 2024

•

Verified SHC Patient

Dr. Witteles was excellent explaining my situation and how we should proceed with my treatment. He made feel at ease with my situation.

Aug 2024

•

Verified SHC Patient

He is so professional and nice , kind, and his team as well. Thanks for him and his team did all for me

Jul 2024

•

Verified SHC Patient

Dr. Ronald Witteles is an excellent and very caring doctor. He takes the time to listen and comment on my condition. He is very professional and sympathetic.

Jul 2024

•

Verified SHC Patient

Excellent Doctor who is caring and knowledgeable about my disease.

Jun 2024

•

Verified SHC Patient

The best. I have an extensive medical background and I am often treated by ill prepared care givers. I trust Dr. Witteles and feel safe and secure in following his recommendations.

Jun 2024

•

Verified SHC Patient

Dr. Witteles is amazing !!!

Jun 2024

•

Verified SHC Patient

Great doctor. Always explains everything and very clearly. Explains treatment options and recommendations. Knows what potential new therapies are coming and how they may apply to me.

Jun 2024

•

Verified SHC Patient

Dr. Witteles is very helpful and knowledgeable with my health problem. He provides the most current medical advances with amyloid. I feel that I am in the best of hands with Dr. Witteles.

May 2024

•

Verified SHC Patient

very efficient and had all my medical records ready to discuss

May 2024

•

Verified SHC Patient

Dr. Ronald Witteles was very professional, informative, knowledgeable and very concerned about my condition and health. I was very pleased with the care he provided.

May 2024

•

Verified SHC Patient

He is an excellent doctor and seems genuinely concerned about my situation.

Apr 2024

•

Verified SHC Patient

great doctors also did not have to wait in lobby for a long time

Apr 2024

•

Verified SHC Patient

Understanding and caring physician.

Apr 2024

•

Verified SHC Patient

i am very grateful that Dr Witteles is very familiar with my medical history and incorporates that information when making recommendations and changes to my medical plan and prescriptions. .

Jan 2024

•

Verified SHC Patient

Great doctor!

Jan 2024

•

Verified SHC Patient

Dr. Wittles showed up at the meeting with a very good understanding of my case history and situation, provide and excellent background of Amyloidosis, in general and my specific flavor in particular. He initially told me that my heart was OK, which was what I was really worried about today (he knew that I'm guessing), and then asked some questions about my current state, and then provided and excellent and detailed summary of my medical voyage so far, and what the next steps would be. His summary wove in events that occurred within the Mercy Medical system as well as Stanford, and so his notes are the best and most complete description of all my recent medical tests, results, procedures, and symptoms, that I have. We agreed on next steps, and I feel that I very clearly understand my medical situation. I'd like to thank Dr. Witteles for his thorough preparation, and organization during the meeting, as well as his flexibility in answering my questions. This was an excellent visit, and not just because I got good news. The above things would have been even more important to me if I was getting bad news. So in summary it was a great visit, which I am really thankful for.

Dec 2023

•

Verified SHC Patient

Dr. Witteles is very personal, knowledgeable, and easy to talk with. I really like him as my Cardiologist.

Dec 2023

•

Verified SHC Patient

Great appointment. He is always kind, helpful and informative. Great physician!

Dec 2023

•

Verified SHC Patient

I appreciated the opportunity to have the visit virtually.

Nov 2023

•

Verified SHC Patient

Very good visit and productive.

Nov 2023

•

Verified SHC Patient

Great doctor, nice and talked with him about issues.

Oct 2023

•

Verified SHC Patient

An excellent, empathetic doctor.

Oct 2023

•

Verified SHC Patient

Echocardiogram technician was friendly and thorough

Jul 2023

•

Verified SHC Patient

Stanford Medicine is world-class

Jun 2023

•

Verified SHC Patient

Excellent doctor. Very friendly, seems to truly care about me, but always very professional.

May 2023

•

Verified SHC Patient

I thought Ron was well prepared and knowledgeable about my particular issues around the medical diagnosis I am dealing with. He also made me aware of upcoming clinical trials that I might be able to participate in and benefit from. There also was a nice discussion about medication changes, and what benefit they may yield, or not yield.

May 2023

•

Verified SHC Patient

Extremely knowledgeable and very helpful.

May 2023

•

Verified SHC Patient

He was great. Thorough and informative. I learned a lot!

Apr 2023

•

Verified SHC Patient

I appreciate that Dr Witless is very familiar with my case. That allows us to discuss differences in my health without having to verbally recap my medical history and what had been prescribed during the last time period. We ate able to focus on current situation and new changes. He provides my care from an informed position which allows me to have great confidence in his care.

Apr 2023

•

Verified SHC Patient

Dr. Witteles is an excellent physician for my husband's heart condition.

Apr 2023

•

Verified SHC Patient

Excellent

Mar 2023

•

Verified SHC Patient

Iâ€™m very pleased with the quality of care I receive from Dr. Witteles.

Feb 2023

•

Verified SHC Patient

Outstanding physician

Dec 2022

•

Verified SHC Patient

Terrific session based on Dr Wittelesâ€™ expertise, clear analysis and communication.

Dec 2022

•

Verified SHC Patient

answered/addressed my questions and concerns, did not seem rushed, had checked my medical record in Epic and had it available so we could review together

Dec 2022

•

Verified SHC Patient

Dr Witteles is an excellent physician.

Nov 2022

•

Verified SHC Patient

Excellent care

Nov 2022

•

Verified SHC Patient

He is a fantastic doctor who knows his feel very well. I'm very comfortable when I consult with him, with his assessment of my situation, and with the information that he gives me.

Nov 2022

•

Verified SHC Patient

The parking is terrible but the staff is terrific.

Oct 2022

•

Verified SHC Patient

He is a careful, caring doctor.

Oct 2022

•

Verified SHC Patient

Was good

Sep 2022

•

Verified SHC Patient

Excellent Staff and care

Aug 2022

•

Verified SHC Patient

Courtesy and efficient

Aug 2022

•

Verified SHC Patient

He is an outstanding cardiologist!

Aug 2022

•

Verified SHC Patient

Great Doctor

Aug 2022

•

Verified SHC Patient

Loved Dr Witteles.

Aug 2022

•

Verified SHC Patient

Witteles is phenomenal

Aug 2022

•

Verified SHC Patient

Wonderful Doctor. I think the video visit was great but next appointment i would like to see in person

Jul 2022

•

Verified SHC Patient

Superb professional attention from an M.D. who obviously knows his field in depth and up to date

Jun 2022

•

Verified SHC Patient

On-task, communicative, responsive, timely and efficient

Jun 2022

•

Verified SHC Patient

Dr Witteles is very knowledgeable in his field, listens carefully to my questions and explaines everything in an easy to understand way. His entire team is the same way. I feel cared for very well.

Jun 2022

•

Verified SHC Patient

Dr Witteles and his staff are outstanding! Their level of patient care is second to none!

Jun 2022

•

Verified SHC Patient

Interested and very knowledgeable and caring physician.

May 2022

•

Verified SHC Patient

Very thorough.

May 2022

•

Verified SHC Patient

He knows his area of medicine unbelievably well and, although my diagnosis is not curable, made me feel hopeful for the future.

May 2022

•

Verified SHC Patient

Dr. Witteles was professional and very clear in his explanations of the process I should expect.

May 2022

•

Verified SHC Patient

He appears to be an excellent and personable doctor.

Apr 2022

•

Verified SHC Patient

Best Doctor ever

Mar 2022

•

Verified SHC Patient

received personalized attention from all providers

Mar 2022

•

Verified SHC Patient

He is kind, knowledgeable, and very easy to talk with.

Mar 2022

•

Verified SHC Patient

Comprehensive care. Feel well looked after. Thanks

Feb 2022

•

Verified SHC Patient

An outstanding cardiologist. Answers all my questions and genuinely cares about his patients.

Jan 2022

•

Verified SHC Patient

Professional, thorough, polite, and friendly. I left with no unanswered questions.

Jan 2022

•

Verified SHC Patient

Brilliant doctor, very clear and helpful.

Jan 2022

•

Verified SHC Patient

Greatest doctor i ever met

Dec 2021

•

Verified SHC Patient

Thorough, knowledgeable and a pleasure to work with.

Dec 2021

•

Verified SHC Patient

The greatest

Dec 2021

•

Verified SHC Patient

Very professional and helpful team. Love them and recommend without reservation. Thanks!

Nov 2021

•

Verified SHC Patient

Excellent physician and a very kind person!

Nov 2021

•

Verified SHC Patient

I hope we never have to because of the nature of the condition but if we knew someone with similar symptoms we wouldn't hesitate to refer.

Oct 2021

•

Verified SHC Patient

He is an excellent doctor and extremely knowledgeable about my amyloidosis.

Sep 2021

•

Verified SHC Patient

He was great.

Sep 2021

•

Verified SHC Patient

Great doctor, I had no trouble understanding what we were discussing

Sep 2021

•

Verified SHC Patient

Dr. Witteles and his team have always been top notch. I appreciate the attention they give me each time I connect with them.

Sep 2021

•

Verified SHC Patient

Great doctor !!!

Jul 2021

•

Verified SHC Patient

He was very patient and a good listener. He explained everything clearly. I felt at ease speaking to him about my medical problems.In addition, Trish, who works in the office, was very good at paving the way for a successful video conference.

Jul 2021

•

Verified SHC Patient

I am extremely pleased with the care I receive from Dr. Witteles, and from all of his assistants.

Jun 2021

•

Verified SHC Patient

Absolutely

May 2021

•

Verified SHC Patient

I have been seeing him for a few years and always feel well looked after. Don't feel I could be in better hands,

May 2021

•

Verified SHC Patient

Very professional and covers everything about my condition in terms I can understand. You are lucky to have Dr Witteles and his staff!

May 2021

•

Verified SHC Patient

Dr. Wireless had a good understanding of my disease, data and concerns. He addressed everything with knowledge and sincerity.

Apr 2021

•

Verified SHC Patient

Excellent.

Apr 2021

•

Verified SHC Patient

Dr. Witteles is the greatest.

Feb 2021

•

Verified SHC Patient

Dr. Witteles, the Stanford Fellow and nurse have all been very good.

Jan 2021

•

Verified SHC Patient

Dr. Witteles always speaks clearly, listens attentively to questions to include me and my spouse in important decisions.

Dec 2020

•

Verified SHC Patient

They listen, advise and show care.

Oct 2020

•

Verified SHC Patient

Dr. Witteles is excellent. Stanford is fortunate to have such an outstanding physician on its staff.

Sep 2020

•

Verified SHC Patient

I drive over 100 miles to see Dr. Wittles and or his fellow. totally worth it.

Aug 2020

•

Verified SHC Patient

Give me confidence.

Aug 2020

•

Verified SHC Patient

good

Jul 2020

•

Verified SHC Patient

Dr Witteles and staff are AWESOME!

Jun 2020

•

Verified SHC Patient

I wish I was cared for by Dr. Witteles from the onset. About a year ago. He has the experience, knowledge, and care for my case. I feel so fortunate to have him.

Jun 2020

•

Verified SHC Patient

Dr. Witteles is an outstanding cardiologist and takes good care of me.

Jun 2020

•

Verified SHC Patient

Good

Dec 2019

•

Verified SHC Patient

Best doctor in the world bar none.

Dec 2019

•

Verified SHC Patient

Dr. Witteles is Fantastic

Nov 2019

•

Verified SHC Patient

Dr. Witteles is an extremely professional and kind man. He is always clear about my condition and never leaves me w/questions.

Oct 2019

•

Verified SHC Patient

Dr. Witteles saved my life. And has given me a good as can be quality of life. I am a stage 4 congestive heart failure patient. Thanks!

Oct 2019

•

Verified SHC Patient

EXCELLENT.

Oct 2019

•

Verified SHC Patient

I am privileged to have Dr. Witteles as my physician. He combines expertise with kindness and compassion.

Sep 2019

•

Verified SHC Patient

Great doctor!!!

Sep 2019

•

Verified SHC Patient

The Fellow who first spoke with me was engaging and seemed to have time to hear my concerns. The physician I was scheduled to see was quite obviously in a hurry, gave me a cursory evaluation, stood and never sat, changed one medication and sent me on my way. I completed a multi-part form on which I listed numerous symptoms and conditions, none of which were addressed or even acknowledged. I drove a combined 7 hours, waited for another and was briskly dismissed in a matter of just a few minutes. I complained of shortness of breath and pulmonary edema and was hospitalized for two days, AFTER Dr. Witteles assessed me and sent me away. I will never see that doctor again and am reluctant to divulge such information to another physician in this manner again.

Sep 2019

•

Verified SHC Patient

keeps us update on this disease and works with our cardiologist in Walnut Creed

Aug 2019

•

Verified SHC Patient

Dr. Witteles is outstanding and is consistently helpful & informative.

Jul 2019

•

Verified SHC Patient

I had an excellent experience with Dr. Witteles. He is expert in his care and patient and kind.

Jun 2019

•

Verified SHC Patient

I have total confidence in Dr. Witteles.

Jun 2019

•

Verified SHC Patient

My doctor is specialized, so don't know anyone else in my position. However, if I did I would highly recommend him.

Jun 2019

•

Verified SHC Patient

Dr. Witteles is kind, patient, and caring, thank you!!!

May 2019

•

Verified SHC Patient

My wife and I were very impressed with Dr. Witteles. He wasn't rushed and he gave us all the time we needed to ask questions and explore options.

Apr 2019

•

Verified SHC Patient

Dr. Witteles was extremely patient with me. Explained all options clearly.

Apr 2019

•

Verified SHC Patient

Excellent care providers!

Jan 2019

•

Verified SHC Patient

Excellent.

Jan 2019

•

Verified SHC Patient

Dr. Witteles is always very clear in his communication. Very pleasant experience.

Jan 2019

•

Verified SHC Patient

Dr. Witteles is wonderful, engaging and always helpful.

Apr 2018

•

Verified SHC Patient

outstanding physician

Jan 2018

•

Verified SHC Patient

Dr. Witteles is outstanding and answered all my questions clearly and completely.

Nov 2017

•

Verified SHC Patient

Dr. Witteles and Dr. Kawana spent more than an hour explaining my condition, treatment options and follow up plan. Very professional.

Nov 2017

•

Verified SHC Patient

caring and competent physcian

Nov 2017

•

Verified SHC Patient

Dr. Witteles is a superb physician and I am so glad I found him, even though I live in Seattle, WA.

Nov 2017

•

Verified SHC Patient

Dr. Witteles saved my life and I am forever in his debt. He is a bench mark in regard to what a patient needs in a specialist.

Oct 2017

•

Verified SHC Patient

Always take time needed, especially since I drive over 3 hours.

Jul 2017

•

Verified SHC Patient

Dr. Witteles is awesome as is his team!

Jul 2017

•

Verified SHC Patient

dr ron is the bomb

Jul 2017

•

Verified SHC Patient

Dr. Witteles answered every question thoroughly. I was so impressed by the fact that he really wanted me to understand & a very complicated diagnosis. I sing his praises!

Jul 2017

•

Verified SHC Patient

excellent

Jun 2017

•

Verified SHC Patient

I have a very serious heart condition. For the first time since contacting this condition, the doctors I talked to through their care and professionalism, really gave me a sense of hope!

Jun 2017

•

Verified SHC Patient

I am extremely impressed with the quality of service that I am receiving at Stanford Medical Center (Heart Clinic). Thank you!!

May 2017

•

Verified SHC Patient

Wonderful doctor. Very caring and his RN Emily is wonderful too. She returns my emails or phone calls quickly, sensitive to my needs and concerns.

May 2017

•

Verified SHC Patient

Very good!

Apr 2017

•

Verified SHC Patient

Dr. Witteles is very knowledgeable, caring & personable. I would highly recommend him to anyone.

Apr 2017

•

Verified SHC Patient

I am so fortunate to be a patient of Dr. Witteles.

Feb 2017

•

Verified SHC Patient

Dr. Witteles and his nursing staff have been exceptional in the care they provide and the time they take to listen and give me options of treatment specific to my case and make recommendation. All positive so far.

Feb 2017

•

Verified SHC Patient

We also love Dr. Witteles!

Jan 2017

•

Verified SHC Patient

Exam was very thorough. Discussions were excellent.

Dec 2016

•

Verified SHC Patient

Dr. Witteles and his staff were excellent, clear, and took the time to hear and answer my concerns about a difficult turn in my course of treatment.

Nov 2016

•

Verified SHC Patient

Dr. Witteles was excellent - I was very impressed!

Nov 2016

•

Verified SHC Patient

He is the best!

Oct 2016

•

Verified SHC Patient

Dr. Wittelas is very patient and excellent at going into details when asked. I feel very confident being in his care.

Oct 2016

•

Verified SHC Patient

Dr. Witteles is great.

Oct 2016

•

Verified SHC Patient

If I had any problem with this care provider, I would get another.

Sep 2016

•

Verified SHC Patient

Always willing to spend the time I need, if there is something pressing.

Sep 2016

•

Verified SHC Patient

Dr. Witteles had so much new and good information that I would have loved to have had more time with him. I understand why that likely wasn't possible.

Sep 2016

•

Verified SHC Patient

Both Marie, and Dr. Witteles, were outstanding with the time they spent with us, their explanations and willingness to answer all our questions.

Aug 2016

•

Verified SHC Patient

Dr. Witteles was able to explain complex medical issues in terms that a layman can easily understand.

Aug 2016

•

Verified SHC Patient

Ms. Kimberly Sangalli (PA) physician assistant is a very compassionate and caring person. HER FOLLOW=UP CARE IS OUTSTANDING. My dr. spent enough time with me to explain my problem. My dr. & his PA definitely worth recommending her care to others.

Jul 2016

•

Verified SHC Patient

I felt like Dr. Witteles gave me all the time I needed to understand my condition and treatment plan.

Jun 2016

•

Verified SHC Patient

Dr. Witteles saved my life. He has been the bedrock of my ongoing care and recovery. I have all the confidence in the world in his abilities and his supporting staff. The care at Stanford is world renowned because of doctors such as Dr. Witteles and Dr. Shirley Park. I will continue to sing the praises of Stanford medical to all who will listen.

Jun 2016

•

Verified SHC Patient

Dr. Witteles was very clear & informative. Answered all my questions on a difficult topic.

May 2016

•

Verified SHC Patient

always very carrying and thoughfull

May 2016

•

Verified SHC Patient

Dr. Witteles is exceptional and I feel fortunate to have him available to me.

Apr 2016

•

Verified SHC Patient

I arrived before the scheduled time admitting clerk - courteous, somebody came out waiting room, informed us that Dr. Witteles will be with me shortly. Shortly after, I was called in. Vitals & immediately, the nurse came, discussed problem. Then Dr. Witteles came, & satisfactory explain to me regarding my cardiac consultation - very satisfactorily.

Apr 2016

•

Verified SHC Patient

Care provider was very professional knowledgeable/busy.

Apr 2016

•

Verified SHC Patient

Very pleased with this physician. Extremely knowledgeable about my rare condition, excellent communicator, caring, and patient.

Apr 2016

•

Verified SHC Patient

very good

Apr 2016

•

Verified SHC Patient

Dr. Witteles is great. Very assecesable, spend the required amount of time with me, very friendly

Mar 2016

•

Verified SHC Patient

Always listen with great interest on anything related to my health. The discussion goes highly educational on my part.

Mar 2016

•

Verified SHC Patient

Thanks Dr. Witteles and Dr. Obrian for taking such good care of me!! My pacemaker working great - thank you Dr. Wang and nurses in surgery for making it go so smooth.

Mar 2016

•

Verified SHC Patient

I am sure the Stanford Amloyd Center and staff are the best in the world. Dr. Wittles and Trish are wonderful. I am very confident in their abilities.

Mar 2016

•

Verified SHC Patient

Very good experience & worth recommending to other patients. I LIKE MY DR.

Nov 2015

•

Verified SHC Patient

Very good assistance over the phone.

Nov 2015

•

Verified SHC Patient

My doctors are always very helpful and explain every aspect of my conditions and med!

Nov 2015

•

Verified SHC Patient

As stated previously, working with Kim S. is great. She makes a good team with Dr. W. I have confidence that between the two of them, they know me and my issues.

Aug 2015

•

Verified SHC Patient

I ask a lot of questions, they were all answered.

Aug 2015

•

Verified SHC Patient

All good!

Aug 2015

•

Verified SHC Patient

Great and compassionate shows sincere concern.

Apr 2015

•

Verified SHC Patient

Dr. Witteles clearly outlined the ways systemic sclerosis can affect the heart. He then told me that I haven't been affected in some of those ways. I truly appreciated hearing that. If the day comes that I have true cardiomyopathy from my disease, I know he'll take expert care of me.

Apr 2015

•

Verified SHC Patient

I have the utmost confidence in Dr. Witteles.

Apr 2015

•

Verified SHC Patient

Dr. Witteles was easy to talk to, informative and positive. Good experience.

Mar 2015

•

Verified SHC Patient

My best experience to date.

Jan 2015

•

Verified SHC Patient

Good.

Apr 2014

•

Verified SHC Patient

Dr. Witteles is an expert in explaining the disease and gave me & my family adequate time.

Feb 2014

•

Verified SHC Patient

View More Patient Reviews

Referring Physicians

PHYSICIAN HELPLINE

Phone: 1-866-742-4811
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.

Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.

You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.

Send referrals online
Place radiology and lab orders
View referral status
Access medical records

Learn More About MedLink

LOG INTO MEDLINK

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

Ronald Witteles

Cardiologist, Heart failure cardiologist

Get In Touch

Biography

Professional Summary

Education & Certifications

Honors & Awards

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Amyloid Center Stanford, CA

Amyloid Center

Heart Transplant Program Stanford, CA

Heart Transplant Program

Heart Failure Clinic at Stanford Stanford, CA

Heart Failure Clinic at Stanford

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(175 reviews)

Referring Physicians

PHYSICIAN HELPLINE

New to MyHealth?

ALREADY HAVE AN ACCESS CODE?

DON'T HAVE AN ACCESS CODE?

NEED MORE DETAILS?

MyHealth for Mobile

WELCOME BACK

Ronald Witteles

Cardiologist, Heart failure cardiologist

Get In Touch

Biography

Professional Summary

Education & Certifications

Honors & Awards

Administrative Appointments

Publications

Clinical Trials

Specializing In

Practice Locations

Amyloid Center Stanford, CA

Amyloid Center

Heart Transplant Program Stanford, CA

Heart Transplant Program

Heart Failure Clinic at Stanford Stanford, CA

Heart Failure Clinic at Stanford

Important Information about Our Organizations and Physician Affiliation

Patient Ratings

How Our Ratings Work

Patient Reviews

(175 reviews)

Referring Physicians

PHYSICIAN HELPLINE